Phase II clinical trial of surgical intervention following chemotherapy for synchronous and metachronous liver metastasis from gastric cancer.
Phase 2
Recruiting
- Conditions
- Patients with synchronous or metachronous liver metastasis from gastric cancer
- Registration Number
- JPRN-UMIN000011445
- Lead Sponsor
- Department of Surgery, Osaka University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients with difficulty in oral intake. 2) Patients with contraindication for administration of S-1, Cisplatin, Docetaxel, Capecitabine, Trastuzumab, and 5 FU. 3)Patients with other kinds of active cancers overlapping gastric cancer. 4) Patients with evidence of peritoneal dissemination or metastatic lesion other than liver (eg. bone, brain). 5) Patients with a history of bone metastasis.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Three years overall survival rate of patient who achieved curative treatment.
- Secondary Outcome Measures
Name Time Method Rate of complete resction (surgical resection), and rate of curative treatment (include intervention of RFA or MCT) for hepatic lesion. Safety of procedure (rate of intra/post operative adverse events), recurrence-free survival time of curative treatment case, and overall survival time of registered patients.